Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $34
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $25 to $34.
Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $25 to $34.